|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
| We’re going down soon, to move to a new Data Center today. We’ll be up ASAP. Sorry. |
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 10/16/23 Cell MedX Corp. 10-Q 8/31/23 42:1.9M Empire Stock Transf… Inc |
Document/Exhibit Description Pages Size
1: 10-Q Cell Medx Corp. - Form 10-Q SEC Filing HTML 448K
2: EX-31.1 Certification of Principal Executive Officer HTML 16K
3: EX-31.2 Certification of Principal Financial Officer HTML 16K
4: EX-32.1 Certification of Principal Executive Officer HTML 14K
5: EX-32.2 Certification of Principal Financial Officer HTML 14K
11: R1 Document and Entity Information HTML 62K
12: R2 Condensed Consolidated Balance Sheets HTML 83K
13: R3 Condensed Consolidated Balance Sheets - HTML 20K
Parenthetical
14: R4 Condensed Consolidated Statements of Operations HTML 77K
15: R5 Condensed Consolidated Statement of Stockholders' HTML 48K
Deficit
16: R6 Condensed Consolidated Statements of Cash Flows HTML 64K
17: R7 Organization and Nature of Operations HTML 20K
18: R8 Related Party Transactions Disclosure HTML 33K
19: R9 Notes and Advances Payable Disclosure HTML 38K
20: R10 Notes and Advances Payable Disclosure, Current HTML 27K
21: R11 Other Current Assets Disclosure HTML 16K
22: R12 Revenue Disclosure HTML 20K
23: R13 Share Capital Disclosure HTML 21K
24: R14 Related Party Transactions Disclosure: Schedule of HTML 22K
Amounts Due to Related Parties (Tables)
25: R15 Related Party Transactions Disclosure: Schedule of HTML 22K
Transactions with Related Parties (Tables)
26: R16 Notes and Advances Payable Disclosure: Schedule of HTML 29K
Loans and Advances Outstanding to Related Parties
(Tables)
27: R17 Notes and Advances Payable Disclosure, Current: HTML 26K
Schedule of notes and advances payable (Tables)
28: R18 Revenue Disclosure: Schedule of Revenue and HTML 20K
Associated Costs (Tables)
29: R19 Organization and Nature of Operations (Details) HTML 17K
30: R20 Related Party Transactions Disclosure: Schedule of HTML 27K
Amounts Due to Related Parties (Details)
31: R21 Related Party Transactions Disclosure: Schedule of HTML 24K
Transactions with Related Parties (Details)
32: R22 Notes and Advances Payable Disclosure: Schedule of HTML 29K
Loans and Advances Outstanding to Related Parties
(Details)
33: R23 Notes and Advances Payable Disclosure (Details) HTML 63K
34: R24 Notes and Advances Payable Disclosure, Current: HTML 28K
Schedule of notes and advances payable (Details)
35: R25 Notes and Advances Payable Disclosure, Current HTML 18K
(Details)
36: R26 Other Current Assets Disclosure (Details) HTML 18K
37: R27 Revenue Disclosure: Schedule of Revenue and HTML 35K
Associated Costs (Details)
40: XML IDEA XML File -- Filing Summary XML 68K
38: XML XBRL Instance -- cmxc-20230831_htm XML 412K
39: EXCEL IDEA Workbook of Financial Report Info XLSX 47K
6: EX-101.CAL XBRL Calculations -- cmxc-20230831_cal XML 47K
7: EX-101.DEF XBRL Definitions -- cmxc-20230831_def XML 180K
8: EX-101.LAB XBRL Labels -- cmxc-20230831_lab XML 326K
9: EX-101.PRE XBRL Presentations -- cmxc-20230831_pre XML 277K
10: EX-101.SCH XBRL Schema -- cmxc-20230831 XSD 77K
41: JSON XBRL Instance as JSON Data -- MetaLinks 164± 239K
42: ZIP XBRL Zipped Folder -- 0001393905-23-000350-xbrl Zip 91K
| Certification of Principal Executive Officer |
CELL MEDX CORP.
CERTIFICATIONS PURSUANT TO
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, Dwayne Yaretz, certify that:
1. I have reviewed this Quarterly Report on Form 10-Q for the period ending August 31, 2023, of Cell MedX Corp.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an Annual Report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Date: October 16, 2023
/s/ Dwayne Yaretz
Dwayne Yaretz
Chief Executive Officer
(Principal Executive Officer)
| This ‘10-Q’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 10/16/23 | None on these Dates | ||
| For Period end: | 8/31/23 | |||
| List all Filings | ||||